30 search results for: coexisting diseases

Itch in AD, PN and CSU: Role of Type 2 Inflammation
expert video

Itch in AD, PN and CSU: Role of Type 2 Inflammation

Dermatology
Review the role of type 2 inflammation in the skin manifestations and itch in these chronic skin conditions.
View more
Can advanced systemic therapies modify pathomechanisms in AD?
expert video

Can advanced systemic therapies modify pathomechanisms in AD?

Dermatology
Dr. Ramien discusses evidence showing that advanced therapies can modify the mechanisms of atopic dermatitis, improving skin barrier function, normalizing the skin microbiome, and reducing chronic itch.
View more
Can early intervention modify the course of AD?
expert video

Can early intervention modify the course of AD?

Dermatology
Dr. Amy Paller emphasizes that early intervention in children can alter disease progression. Depending on the severity, this can be achieved with topical interventions or systemic therapies.
View more
What proportion of patients can achieve control in CRSwNP?
expert video

What proportion of patients can achieve control in CRSwNP?

Rhinology
Join Prof. Hellings and Prof. Corso in dicussion on the factors affecting complete control of CRSwNP, including treatment types, comorbidities, and the need for more data on biologics.
View more
Type 2 Inflammation Underpins Pediatric Severe Asthma
Infographic

Type 2 Inflammation Underpins Pediatric Severe Asthma

Pulmonology
Learn about the role type 2 inflammation plays in the burden and pathophysiology of severe asthma in pediatric patients.
View more
Mast Cells and the Neuroimmune Axis in CSU
expert video

Mast Cells and the Neuroimmune Axis in CSU

Dermatology
A review of the neuroimmune mechanisms and activation of mast cells that result in itch in CSU.
View more
Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion

Dermatology
Panel discussion exploring how itch differs across AD, PN, and CSU, and how it affects pediatric patients with AD.
View more
Neuroimmune Axis in Atopic Dermatitis
expert video

Neuroimmune Axis in Atopic Dermatitis

Dermatology
A review of the neuroimmune mechanisms and changes to skin barrier that result in itch in AD.
View more
Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​

Dermatology
A review of the shared and unique neuroimmune mechanisms in the generation of itch across AD, PN, and CSU.
View more
Neuroimmune Axis and Neuroinflammation in PN
expert video

Neuroimmune Axis and Neuroinflammation in PN

Dermatology
A review of the neuroimmune mechanisms and changes to the dermis that result in itch in PN.
View more
Atopic Dermatitis in Children: Not Just a Skin Disease
expert video

Atopic Dermatitis in Children: Not Just a Skin Disease

Dermatology
In this video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Mark Boguniewicz discusses the multidimensional and cumulative disease burden of AD and its associated comorbidities in children. Dr Boguniewicz also highlights the burden experienced by caregivers of children with AD
View more
The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health
expert video

The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health

Dermatology
Dr. Marlies de Graaf highlights the potential long-term consequences of AD in children.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Saudi ArabiaChange country/region